Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada

INTRODUCTION: New requirements in Canada’s pricing processes for patented drugs may exacerbate delays in regulatory and reimbursement reviews. This study seeks to better understand the impact of any additional delays on non-small cell lung cancer (NSCLC) patients by measuring the following: (a) dura...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanderpuye-Orgle, Jackie, Erim, Daniel, Qian, Yi, Boyne, Devon J., Cheung, Winson Y., Bebb, Gwyn, Shah, Ariel, Pericleous, Louisa, Maruszczak, Maciej, Brenner, Darren R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886863/
https://www.ncbi.nlm.nih.gov/pubmed/35230672
http://dx.doi.org/10.1007/s40487-022-00187-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886863/
https://www.ncbi.nlm.nih.gov/pubmed/35230672
http://dx.doi.org/10.1007/s40487-022-00187-3

Ejemplares similares